Application of CYP1B1*3 pharmacogene detection in individualized drug use of paclitaxel
Objective To explore the correlation between CYP1B1*3 gene polymorphism and adverse reactions of Paclitaxel in tumor patients,and to test the effect of this gene in guiding safe medication,so as to provide scientific basis for the precise use of paclitaxel in clinic.Methods This study was divided into two parts:① Selected 104 tumor patients who received paclitaxel chemotherapy in our hospital from Aug 2019 to Dec 2021 as the research objects,and used fluorescence in situ hybridization(FISH)to detect the CYP1B1*3(1294 C>G)genotype.Observed,collected and recorded the occurrence of adverse drug reactions(ADR),finded out the ADR caused by paclitaxel through drug association evaluation,and analyzed the correlation between ADR and CYP1B1*3 gene polymorphisms;② Selected 60 tumor patients who received paclitaxel chemotherapy from Jan to Apr 2022 were randomly divided into individualized medication group(30 cases)and routine treatment group(30 cases).The individualized medication group underewent CYP1B1*3(1294 C>G)gene testing and adjusted the dosage besed on the genetic results and individual patient conditions.The routine treatment group without genetic screening was administered according to the standard dosage,and the incidence of adverse reactions were compared between the two groups.Results In the gene correlation study,the incidence of myelosuppression,gastrointestinal reactions in patients with CYP1B1*3 wild-type gene were significantly higher than those with mutant gene,and the differences were statistically significant(P<0.05).In the individualized medication study,the incidence of adverse reactions of paclitaxel in the individualized medication group was significantly lower than that in the routine treatment group,and the difference was statistically significant(P<0.05).Conclusion The CYP1B1*3 gene polymorphism is associated with the adverse reactions of paclitaxel.The detection of CYP1B1*3 gene can improve the safety of paclitaxel in tumor patients.
NETL
NSTL
万方数据
